Research firm Taglich Brothers has initiated coverage on ALR Technologies, Inc. (OTCBB: ALRT); issuing a “Speculative Buy” rating and a $0.50 12-month price target on the healthcare technology company and developer of the Health-e-Connect (HeC) system.  HeC is an FDA-cleared Internet-based system from chronic disease management.  A scalable technology for a wide array of chronic diseases, HeC is initially being marketed by ALR Technologies as a solution for better diabetes management, a multi-billion dollar industry.

Shares of ALRT closed at $0.09 on Wednesday and are trading up by 10 percent at $0.099 in early Thursday morning trading.

According to the Taglich report,

“Internet-Based Glucose Monitoring Systems (IBGMS) are poised to assume a key, lucrative role in the management of millions of diagnosed US diabetics.

One such system, ALR’s Health-e-Connect (HeC), offers a low-cost, universally compatible means of facilitating effective disease management through the exchange of patient self-monitored diagnostic data and clinician feedback over the Internet.”

Taking a succinct look at the industry, the report analyzes market trends and future growth as well as drawing comparisons of ALRT to its industry peers.  Other components of the analysis include target markets for ALRT (health insurers, pharmaceutical manufacturers and pharmacies), discussions of benefits of adopting technologies like ALRT’s by Medicare, the proven benefits of glucose monitoring technologies, competitors and much more.

The investment community is encouraged to download and read the complete Taglich Brothers Analyst Report on ALR Technologies.

ALR Technologies (ALRT) Stock Quote and News:

---

Disclaimer: Neither http://www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated three thousand dollars for one month of consultation and journalism services and to manage an investor relations/awareness program by ALR Technologies. Viper has completed prior service agreements with ALRT Technologies with full disclosure listed on our disclaimer/disclosure page. Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.